SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Indications -- Lupus/Nephritis
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: keokalani'nui who wrote (8)4/17/2001 3:36:45 PM
From: keokalani'nui  Read Replies (1) of 95
 
CTLA4 Ig. Mention in same link. Didn't know about PDLI's efforts. (No obviously mentioned in 10K or home page, is this accurate?)

Costimulatory blockers represent the most intriguing new strategy for lupus treatment, Decision Resources says in a report. The agents, which are in early stages of development, include Bristol-Myers Squibb’s humanized antibody BMS-188667 and Protein Design Labs’ CTLA4-Ig antibody. The most fundamental market need is a better understanding of lupus etiology to guide development of therapeutics with increased efficacy and reduced side effects.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News